Header Logo

Connection

CRISTINA POVEDA to Chagas Disease

Back to Details
This is a "connection" page, showing publications CRISTINA POVEDA has written about Chagas Disease.
CRISTINA POVEDA
Connection Strength
5.815
Chagas Disease
  1. Microbiome Profiling in Chagas Disease: Sample Collection, Sequencing, and Analysis. Methods Mol Biol. 2026; 3013:265-297.
    View in: PubMed
    Score: 0.700
  2. Parasite-microbiota interactions: a pathway to innovative interventions for Chagas disease, leishmaniasis, and ascariasis. Future Microbiol. 2025 02; 20(2):149-161.
    View in: PubMed
    Score: 0.648
  3. Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease. ACS Appl Mater Interfaces. 2024 Apr 03; 16(13):15832-15846.
    View in: PubMed
    Score: 0.619
  4. Mining the Metabolome for New and Innovative Chagas Disease Treatments. Trends Pharmacol Sci. 2021 01; 42(1):1-3.
    View in: PubMed
    Score: 0.492
  5. A systematic review of the Trypanosoma cruzi genetic heterogeneity, host immune response and genetic factors as plausible drivers of chronic chagasic cardiomyopathy. Parasitology. 2019 03; 146(3):269-283.
    View in: PubMed
    Score: 0.422
  6. Ecology of Trypanosoma cruzi I genotypes across Rhodnius prolixus captured in Attalea butyracea palms. Infect Genet Evol. 2017 04; 49:146-150.
    View in: PubMed
    Score: 0.376
  7. Therapeutic potential of hookworm proteins in promoting regulatory immune responses to modulate Trypanosoma cruzi induced liver inflammation and oxidative stress. Mem Inst Oswaldo Cruz. 2026; 121:e250123.
    View in: PubMed
    Score: 0.176
  8. Towards a map of the immune system manipulation network by Trypanosoma cruzi. Front Cell Infect Microbiol. 2025; 15:1711520.
    View in: PubMed
    Score: 0.175
  9. RNA Sequence Analysis in Macrophages Infected With Trypanosoma cruzi: Focus on TLR2 and TLR7, Iron Metabolism, and Extracellular Matrix Biosynthesis. J Infect Dis. 2025 Jul 11; 231(6):e1102-e1113.
    View in: PubMed
    Score: 0.169
  10. Different responses involving Tfh cells delay parasite-specific antibody production in Trypanosoma cruzi acute experimental models. Front Immunol. 2025; 16:1487317.
    View in: PubMed
    Score: 0.167
  11. Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate. PLoS Pathog. 2024 12; 20(12):e1012764.
    View in: PubMed
    Score: 0.163
  12. Adaptation of Chagas Disease Screening Recommendations for a Community of At-risk HIV in the United States. Clin Infect Dis. 2024 02 17; 78(2):453-456.
    View in: PubMed
    Score: 0.154
  13. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2023 11; 17(11):e0011519.
    View in: PubMed
    Score: 0.151
  14. Microbiome Alterations Driven by Trypanosoma cruzi Infection in Two Disjunctive Murine Models. Microbiol Spectr. 2023 06 15; 11(3):e0019923.
    View in: PubMed
    Score: 0.146
  15. Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. Expert Rev Vaccines. 2022 09; 21(9):1185-1203.
    View in: PubMed
    Score: 0.137
  16. Signal Transducer and Activator of Transcription-3 Modulation of Cardiac Pathology in Chronic Chagasic Cardiomyopathy. Front Cell Infect Microbiol. 2021; 11:708325.
    View in: PubMed
    Score: 0.129
  17. Autoantibodies against the immunodominant sCha epitope discriminate the risk of sudden death in chronic Chagas cardiomyopathy. Ann N Y Acad Sci. 2021 08; 1497(1):27-38.
    View in: PubMed
    Score: 0.125
  18. Interaction of Signaling Lymphocytic Activation Molecule Family 1 (SLAMF1) receptor with Trypanosoma cruzi is strain-dependent and affects NADPH oxidase expression and activity. PLoS Negl Trop Dis. 2020 09; 14(9):e0008608.
    View in: PubMed
    Score: 0.121
  19. Genomic assemblies of newly sequenced Trypanosoma cruzi strains reveal new genomic expansion and greater complexity. Sci Rep. 2018 10 02; 8(1):14631.
    View in: PubMed
    Score: 0.106
  20. L-arginine supplementation reduces mortality and improves disease outcome in mice infected with Trypanosoma cruzi. PLoS Negl Trop Dis. 2018 01; 12(1):e0006179.
    View in: PubMed
    Score: 0.101
  21. Altered bone marrow lymphopoiesis and interleukin-6-dependent inhibition of thymocyte differentiation contribute to thymic atrophy during Trypanosoma cruzi infection. Oncotarget. 2017 Mar 14; 8(11):17551-17561.
    View in: PubMed
    Score: 0.095
  22. Prevalence of Trypanosoma cruzi's Discrete Typing Units in a cohort of Latin American migrants in Spain. Acta Trop. 2016 May; 157:145-50.
    View in: PubMed
    Score: 0.088
  23. Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection. PLoS Negl Trop Dis. 2015; 9(8):e0004025.
    View in: PubMed
    Score: 0.085
  24. Global metabolomic profiling of acute myocarditis caused by Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2014 Nov; 8(11):e3337.
    View in: PubMed
    Score: 0.081
  25. Cytokine profiling in Chagas disease: towards understanding the association with infecting Trypanosoma cruzi discrete typing units (a BENEFIT TRIAL sub-study). PLoS One. 2014; 9(3):e91154.
    View in: PubMed
    Score: 0.077
  26. Distribution of Trypanosoma cruzi discrete typing units in Bolivian migrants in Spain. Infect Genet Evol. 2014 Jan; 21:440-2.
    View in: PubMed
    Score: 0.076
  27. Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2021 09; 15(9):e0009689.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.